Compare
SpyGlass Pharma, Inc. vs Sight Sciences, Inc. vs Orchestra BioMed Holdings, Inc. vs Fractyl Health, Inc.
| Latest fiscal year | SpyGlass Pharma, Inc. SGP | Sight Sciences, Inc. SGHT | Orchestra BioMed Holdings, Inc. OBIO | Fractyl Health, Inc. GUTS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $77.36M | $33.48M | $0 |
| Revenue growth (YoY) | n/a | -3.1% | n/m | -100.0% |
| Gross margin | n/a | 86.2% | n/a | n/a |
| Operating margin | n/a | -48.0% | -154.7% | n/a |
| Net margin | n/a | -49.7% | -157.4% | n/a |
| Net income | -$39.87M | -$38.43M | -$52.70M | -$140.95M |
| EPS (Diluted) | -$17.98 | -$0.74 | -$1.11 | -$1.86 |
| Operating cash flow | -$32.70M | -$29.69M | -$48.96M | -$90.33M |
| Free cash flow | -$33.49M | -$29.92M | -$49.45M | -$90.89M |
| Cash & equivalents | $96.36M | $91.97M | $34.69M | $81.54M |
| Total assets | $115.87M | $115.30M | $114.86M | $121.40M |
| Total liabilities | $10.17M | $51.36M | $51.48M | $111.94M |
| Shareholders' equity | -$98.84M | $63.94M | $53.57M | $9.46M |
| Return on year-end equity | n/a | -60.1% | -98.4% | n/m |
| Shares outstanding | 2.20M | 53.49M | 57.03M | 153.37M |
Revenue, most recent five fiscal years
| Fiscal year | SpyGlass Pharma, Inc. | Sight Sciences, Inc. | Orchestra BioMed Holdings, Inc. | Fractyl Health, Inc. |
|---|---|---|---|---|
| Latest | n/a | $77.36M Ended 2025-12-31 | $33.48M Ended 2025-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $79.87M Ended 2024-12-31 | $2.64M Ended 2024-12-31 | $93.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $81.06M Ended 2023-12-31 | $2.76M Ended 2023-12-31 | $120.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $71.33M Ended 2022-12-31 | $3.53M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $48.96M Ended 2021-12-31 | n/a | n/a |